Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
EBS Transcript
Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript
Positive5-1
The earnings call highlights strong financial health, with improved cash balance, reduced debt, and increased liquidity. The company's international MCM revenue shows strategic growth, with higher margins and diversification. The Q&A section indicates optimism for the naloxone market and international demand for MCM products. Despite some unclear responses, the overall sentiment is positive due to cost management, share repurchase, and strategic expansion efforts.
Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript
Positive2-26
Emergent reported a 10% YoY revenue increase, improved gross margins, and turned a net loss into a net income, which are strong financial indicators. The raised guidance for revenue and EBITDA, along with strategic government partnerships, supports a positive outlook. Despite the absence of dividend or buyback announcements, the financial and strategic updates suggest a likely stock price increase in the short term.
Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript
Positive10-29
The earnings call highlights strong financial performance, with revenue exceeding guidance and improved EBITDA margins. The company has raised its EBITDA guidance and achieved significant cost reductions. The Q&A section reveals positive analyst sentiment, with interest in international growth and diversified MCM products. Despite some variability in NARCAN sales, the overall outlook is optimistic with strategic partnerships and a share repurchase program. These factors suggest a positive stock price movement over the next two weeks.
Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call reveals strong financial performance with revenue exceeding guidance and improved profitability metrics. The share repurchase program and improved liquidity are positive signals. While there are strategic risks and economic uncertainties, the company's strategic initiatives, such as the expansion of NARCAN and international sales, are promising. The Q&A section indicates stable pricing and market share for NARCAN, and potential revenue from contract modifications. Overall, the financial health and strategic direction suggest a positive outlook.
EBS Slides
EBS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
